RxDoctor Payments Data

Vinay Thohan, MD

Advanced Heart Failure and Transplant Cardiology · Asheville, NCNPI 1184650798

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $122,046 of the $164,164 with a category attached, or 74.3%. 26 manufacturers reported payments, led by Boehringer Ingelheim at 44.8% of the total. Reporting peaked in 2022 at $38,260 and has fallen 55.2% since, to $17,139 in 2025.

$164,164in general payments, 2019–2025

Across 446 payments — averaging $368.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$74K
  • Pfizer$45K
  • Impulse Dynamics (USA) Inc.$16K
  • Lilly USA, LLC$10K
  • Abbott$10K
  • E.r. Squibb & Sons, L.L.C.$6K
  • plus $5K from 20 others
$22,942in research payments, 2019–2025

Across 8 payments — averaging $2867.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$23K

What the payments were for

  • Consulting fees$15,1339%
  • Speaking & faculty fees$122,04674%
  • Travel & lodging$13,3908%
  • Food & beverage$13,4678%
  • Education$1290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$164,164 in reported general payments places this provider in the 80th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.

See all advanced heart failure and transplant cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$117,682
Medicare patients
321
Services billed
1,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis172$4,019,845
AdempasRiociguat101$1,364,044
Tyvaso DpiTreprostinil37$895,786
OpsumitMacitentan59$744,712
Orenitram ErTreprostinil Diolamine49$587,449
UptraviSelexipag21$436,337
JardianceEmpagliflozin377$393,894
CamzyosMavacamten42$337,167
EntrestoSacubitril/Valsartan258$320,280
VyndaqelTafamidis Meglumine13$290,398
EliquisApixaban213$201,914
FarxigaDapagliflozin Propanediol61$62,287
XareltoRivaroxaban33$35,778
Ambrisentan15$18,657
Tadalafil22$12,833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$45,105$4,512,157398 claims
BayerAdempas$1,346$1,364,044101 claims
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$817$1,181,04980 claims
Boehringer IngelheimJardiance$73,586$393,894377 claims
E.r. Squibb & Sons, L.L.C.Camzyos$5,507$337,16742 claims
NovartisEntresto$44$320,280258 claims
AstraZenecaFarxiga$171$62,28761 claims
AmgenCorlanor$147$9,83611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.

Other advanced heart failure and transplant cardiology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →